Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 29, 2006

DOR Biopharma Awarded $5.3M to Advance Ricin Toxin and Botulinum Toxin Vaccine Programs

  • DOR BioPharma was awarded two additional grants from the NIAID totaling approximately $5.3 million to support the development of its biodefense vaccine programs. One grant of approximately $4.8 million was awarded for the continued development of RiVax™, a recombinant vaccine against ricin toxin. The second grant of approximately $0.5 million was awarded to continue additional research on the development of BT-VACC™, a multivalent mucosal vaccine against botulinum toxin.

    The RiVax™ grant is over a three-year period and will fund the development of animal models that will be used to correlate human immune response to the vaccine with protective efficacy in animals. This new grant also supports the further biophysical characterization of the vaccine containing a well-characterized adjuvant that is needed to enhance the immune response to recombinant proteins.

    DOR’s second grant will be used to conduct further work to combine antigens from different serotypes of botulinum toxin for a prototype multivalent vaccine. The grant funding will support further work in characterizing antigen formulations that induce protective immunity to the three most common botulinum toxin types that may be encountered naturally or in the form of a bioweapon.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »